HLA‐DQA1‐HLA‐DRB1 polymorphism is a major predictor of azathioprine‐induced pancreatitis in patients with inflammatory bowel disease - Wilson, A.; Jansen, L. E.; Rose, R. V.; Gregor, J. C.; Ponich, T.; Chande, N.; Khanna, R.; Yan, B.; Jairath, V.; Khanna, N.; Sey, M.; Beaton, M.; et al. (Alimentary pharmacology & therapeutics, 2018)
Keywords: 6-Mercaptopurine; Adult; Azathioprine; Azathioprine - adverse effects; Azathioprine - therapeutic use; Canada; Case-Control Studies; Clinical medicine; Cohort Studies; DQA1 protein; Drb1 protein; Female; Gene polymorphism; Genome-wide association studies; Genome-Wide Association Study; Genomes; Genotype; Genotypes; Haplotypes; Histocompatibility antigen HLA; HLA-DQ alpha-Chains - genetics; HLA-DRB1 Chains - genetics; Humans; Inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - genetics; Intestine; Male; Middle Aged; Pancreatitis; Pancreatitis - chemically induced; Pancreatitis - genetics; Pharmacogenetics; Pharmacogenomics; Polymorphism, Single Nucleotide; Retrospective Studies; Single-nucleotide polymorphism; Canada